Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious and inflammatory mediated diseases. The Immuron news feed on Stock Titan aggregates company announcements, market updates and regulatory disclosures so readers can follow developments around its commercial products and clinical pipeline.
News about Immuron frequently highlights Travelan®, an over‑the‑counter immune supplement and dietary supplement based on hyper‑immune bovine antibodies that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Company updates have reported record Travelan sales in Australia and North America, marketing initiatives in retail and online channels, and clinical trial activity involving IMM‑124E, the active ingredient in Travelan, in collaboration with the Uniformed Services University.
Investors and followers can also expect coverage of pipeline milestones such as FDA interactions and clinical plans for IMM‑529, a candidate for Clostridioides difficile infection, and IMM‑986, a pre‑clinical program targeting vancomycin‑resistant enterococci. Immuron’s announcements describe pre‑clinical results, Investigational New Drug submissions and approvals, and collaborations with institutions including Naval Medical Research Command, Walter Reed Army Institute of Research and Monash University.
In addition, the news stream includes letters to shareholders, sales updates, distribution agreements such as the ProIBS® IBS product in Australia and New Zealand, and corporate communications about investor engagement initiatives. Bookmark this page to access a consolidated view of Immuron’s operational, clinical, commercial and corporate news as it is released through official channels.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a strategic shift on August 19, 2022, deprioritizing its SARS-CoV-2 research to focus on advanced therapeutic drug candidates. The company is entering FY23 with a new CEO assessing its product portfolio and growth strategies. Immuron's previous research indicated the potential antiviral activity of its drug candidate IMM-124E against SARS-CoV-2, but the mechanism of action remains unclear. The evolving virus and treatment landscape pose challenges for clinical trials.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that the US Naval Medical Research Center (NMRC) received feedback from the US FDA regarding its Investigational New Drug (IND) application for a new oral therapeutic targeting Campylobacter and ETEC. The FDA identified insufficient information under 21 CFR 312.23 for assessing risks in proposed clinical studies, placing the IND on Clinical Hold. NMRC plans to address these comments and will seek a Type A meeting with the FDA within 30 days to discuss amendments and requirements for moving forward.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported significant sales growth for FY22. North American sales of Travelan® surged by 494%, reaching AU $0.6M, while global sales rose 431% to AU $0.9M. Sales in the US were particularly strong, increasing from AU $4K in FY21 to AU $0.6M in FY22, driven by sales through Passport Health Travel Clinics and Amazon. In Australia, sales of Travelan® and Protectyn® also grew, totaling AU $0.3M in FY22. Immuron aims to expand its product portfolio while benefiting from the recovering travel sector.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced receiving a notification of the Intent to Grant a European Patent for treatments related to Clostridioides difficile associated disease. This patent, numbered 14784945.9, focuses on methods and compositions for both treatment and prevention of the infection. Alongside patents in Australia, New Zealand, and the U.S., this grant strengthens Immuron's intellectual property in an area with significant health and economic impact, as Clostridioides difficile infections can result in severe complications and considerable healthcare costs globally.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced that the US Naval Medical Research Center (NMRC) submitted an IND application to the FDA for a new oral therapeutic targeting Campylobacter and ETEC. This initiates two human phase II clinical trials, with one trial aimed at preventing infectious diarrhea caused by ETEC, set to start in July 2022, and another focused on moderate to severe campylobacteriosis. The trials will recruit 60 volunteers, testing the product's safety and efficacy against these pathogens.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) provides an update on its clinical trial evaluating the efficacy of Travelan® against two non-antibiotic products for Travelers’ Diarrhea (TD). Manufacture of investigational medical products is complete, and initial shipments have been dispatched. The clinical protocol has been amended to extend the treatment period from 13 to 22 days due to COVID-19 quarantine requirements. Planned enrollment of 1,336 participants is expected to begin in June 2022, with completion anticipated within 18 months.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Steven Lydeamore as CEO, effective June 27, 2022. With 30 years of pharmaceutical experience, including roles at Apotex and Mayne Pharma, Lydeamore has a strong background in mergers, acquisitions, and product development. He aims to leverage opportunities for Immuron's products, Travelan® and Protectyn®, and enhance the company's IP portfolio. Interim CEO Dr. Jerry Kanellos will transition to COO, acknowledging the challenges faced during his tenure. The company is focused on expanding clinical trials in partnership with the U.S. Department of Defense.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported strong sales growth for its gastrointestinal supplement Travelan® in Q3 FY22. North American sales surged 185% year-over-year, while global sales increased by 216%, totaling AU $193K compared to AU $61K in Q3 FY21. Year-to-date results show AU $392K in worldwide sales, marking a 340% increase. Sales in the US reached AU $153K for Q3 FY22, primarily driven by partnerships with Passport Health Travel Clinics and e-commerce platforms. Positive sales trends are attributed to the recovery of international travel.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has made significant progress in its bid for additional funding from the U.S. Department of Defense. The company is seeking AU$5.4M (US$4M) for its Travelan product, deemed eligible for award. The Investigational New Drug application is advancing, with plans for a clinical trial involving 60 healthy volunteers in the USA. This trial will focus on preventing travelers' diarrhea caused by bacterial pathogens, amidst concerns regarding antibiotic resistance and the need for effective preventive treatments.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Paul Brennan as an independent Non-Executive Director, effective March 16, 2022. Brennan's extensive healthcare experience includes his role as CEO of PolyNovo Limited, where he grew the company significantly. His appointment is expected to leverage Immuron's unique intellectual property in gut health and enhance its clinical research capabilities. Non-Executive Chairman Dr. Roger Aston expressed confidence in Brennan's diverse background, which includes technology commercialization and international marketing.